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Abstract
Background: Skin fibrosis is a significant global health problem that affects over 100 million people annually and
has a profoundly negative impact on quality of life. Characterized by excessive fibroblast proliferation and collagen
deposition, skin fibrosis underlies a wide spectrum of dermatologic conditions ranging from pathologic scars secondary
to injury (e.g., burns, surgery, trauma) to immune-mediated diseases. Effective anti-scarring therapeutics remain an unmet
need, underscoring the importance of developing novel approaches to treat and prevent skin fibrosis. Our in vitro data
show that light emitting diode-red light (LED-RL) can modulate key cellular and molecular processes involved in skin
fibrosis. In two phase I clinical trials (STARS 1 and STARS 2), we demonstrated the safety and tolerability of LED-RL at
fluences of 160 J/cm2 up to 480 J/cm2 on normal human skin.
Methods/design: CURES (Cutaneous Understanding of Red-light Efficacy on Scarring) is a dose-ranging, randomized,
parallel group, split-face, single-blind, mock-controlled phase II study to evaluate the efficacy of LED-RL to limit post-
surgical skin fibrosis in subjects undergoing elective mini-facelift surgery. Thirty subjects will be randomly allocated to three
treatment groups to receive LED-RL phototherapy or temperature-matched mock irradiation (control) to either periauricular
incision site at fluences of 160 J/cm2, 320 J/cm2, or 480 J/cm2. Starting one week post-surgery (postoperative days 4–8),
treatments will be administered three times weekly for three consecutive weeks, followed by efficacy assessments at
30 days, 3 months, and 6months. The primary endpoint is the difference in scar pliability between LED-RL-treated and
control sites as determined by skin elasticity and induration measurements. Secondary outcomes include clinical and
photographic evaluations of scars, 3D skin imaging analysis, histological and molecular analyses, and adverse events.
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Discussion: LED-RL is a therapeutic modality of increasing importance in dermatology, and has the potential to limit
skin fibrosis clinically by decreasing dermal fibroblast activity and collagen production. The administration of LED-RL
phototherapy in the early postoperative period may optimize wound healing and prevent excessive scarring. The
results from this study may change the current treatment paradigm for fibrotic skin diseases and help to pioneer LED-
RL as a safe, non-invasive, cost-effective, portable, at-home therapy for scars.
Trial registration: ClinicalTrials.gov, NCT03795116. Registered on 20 December 2018.
Keywords: Light emitting diode, Red light, Phototherapy, Skin fibrosis, Wound healing, Scarring, Hypertrophic scar,
Keloid, Surgery
Background
Skin fibrosis, or scarring, represents an exuberant wound
healing response following tissue damage due to stimuli
such as infection, autoimmune reaction, and mechanical in-
jury [1, 2]. Characterized by excessive fibroblast prolif-
eration and collagen deposition in the dermis, skin
fibrosis is the histopathologic hallmark of a wide
spectrum of dermatologic diseases, including sclero-
derma, chronic graft-versus-host disease, and re-
strictive dermopathy [3, 4]. Localized skin fibrosis
can also develop as a sequela of dermal injury (e.g.,
burns, surgery, trauma), manifested clinically as
hypertrophic scars or keloids [5, 6].
Skin fibrosis is a significant global health problem with
an estimated incidence of greater than 100 million persons
affected per year in the developed world [7, 8]. Cutaneous
scars have a profoundly negative impact on patients’ quality
of life due to associated pain and pruritus, functional im-
pairment, cosmetic disfigurement, and psychosocial distress
[7, 9, 10]. As such, there is high demand for therapeutic
modalities that prevent, reduce, or remove scars, as evi-
denced by an estimated $12 billion annual market for scar
treatment in the US [11]. Despite the substantial socioeco-
nomic burden associated with skin fibrosis, few effective
and durable anti-scarring therapeutics are available, making
scar treatment a major unmet medical need [12–14]. Fur-
thermore, current scar management strategies may be inva-
sive, cause undesirable side effects, or lack high-level
evidence to support their use [12]. Therefore, it is import-
ant to research and develop novel approaches to treat and
prevent skin fibrosis.
Visible light (400–700 nm) is ubiquitous in the envir-
onment and comprises 44% of total solar energy, yet its
biological effects on the skin have not been fully eluci-
dated [15, 16]. Visible light therapy delivered by light
emitting diode (LED) devices is a therapeutic modality
of increasing clinical importance in dermatology, as
different wavelengths can alter skin physiology and
produce beneficial effects such as in wound healing
and skin rejuvenation [17–19]. Due to the significant
advances in LED technology in recent years, LED
phototherapy has become a valuable and effective
treatment for a wide variety of medical and aesthetic
conditions [20]. In 2017, members of the American So-
ciety for Dermatologic Surgery performed more than
3.2 million procedures using lasers, lights, and energy-
based devices [21]. Furthermore, LED devices are
commercially available and have US Food and Drug
Administration (FDA) clearance for various dermatologic
conditions including acne vulgaris and photoaging [19, 22].
Red light (630–700 nm) has the deepest tissue penetration
depth of the visible light colors, reaching the entirety of the
dermis where skin fibrosis occurs [18, 23, 24]. Recently
published clinical observations indicate that red light
in combination with other modalities, such as photo-
sensitizers for photodynamic therapy, can decrease
skin fibrosis [25–27].
According to our in vitro data, light emitting diode-
red light (LED-RL) at high fluences (defined as equal to
or greater than 160 J/cm2) can exert anti-fibrotic cutane-
ous effects by decreasing cellular proliferation, collagen
production, and migration speed of human skin fibro-
blasts [28–31]. Prior to our studies on the anti-fibrotic
properties of LED-RL, limited data existed regarding red
light photobiomodulation of skin fibroblasts. In two
phase I clinical trials, Safety Trial Assessing Red-light on
Skin (STARS 1 and STARS 2), we demonstrated the
safety and tolerability of LED-RL administered at flu-
ences up to 480 J/cm2 on normal forearm skin in healthy
individuals (n = 115 in both trials combined) [32].
Adverse events (AEs) included post-treatment erythema,
hyperpigmentation, and localized bulla formation, all of
which were mild and resolved without permanent seque-
lae (unpublished data).
CURES (Cutaneous Understanding of Red-light Effi-
cacy on Scarring) is a phase II randomized controlled
trial to evaluate the anti-fibrotic effects of LED-RL in
subjects who will undergo elective mini-facelift surgery,
using the periauricular skin incisions as the treatment
sites. To our knowledge, no clinical trials have been per-
formed to determine the safety and efficacy of LED-RL
for skin fibrosis. Developing LED-RL as a modality for
skin fibrosis would represent an important advance in
scar therapy as it would offer many advantages over
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current therapeutic strategies. For example, LED-RL
lacks serious systemic side effects associated with immu-
nomodulatory agents, is non-invasive and avoids the
need for painful injections with anti-fibrotic agents, re-
quires no downtime for the patient, and does not gener-
ate procarcinogenic DNA damage associated with
ultraviolet light therapy [31, 32]. The potential health
impact of this study is significant, as successful demon-
stration of the clinical efficacy of LED-RL to limit post-
surgical skin fibrosis may shift the current treatment
paradigm for various types of scars. Therefore, we intend
to study LED-RL as a standalone therapeutic modality
for skin fibrosis, with the goal of pioneering LED-RL as
a safe, cost-effective, non-invasive, portable, at-home
treatment to reduce scarring.
Methods/design
Hypothesis
LED-RL phototherapy is a safe and effective therapeutic
modality to limit post-surgical skin fibrosis.
Primary outcome measure
Difference in quantitative scar pliability, as determined
by skin elasticity and skin induration, between the
treated and control incision sites.
Secondary outcome measures
 Difference in the Patient and Observer Scar
Assessment Scale (POSAS) scores between the
treated and control incision sites
 Difference in the photograph-based Visual Analogue
Scale (VAS) scores between the treated and control
incision sites
 Difference in the objective measurements of key scar
characteristics (collagen and water concentration,
texture, volume, pigmentation, vascularity) between
the treated and control incision sites
 Histological and molecular analyses of treated and
control skin specimens
 Incidence of AEs
Study setting and population
The study will be conducted at SUNY Downstate
Medical Center. A total of 30 subjects will be en-
rolled. Individuals of any sex, ethnicity, and age who
plan to undergo elective mini-facelift surgery may be
eligible to participate in the study. The clinical re-
search team will screen potential subjects (through in-
terviews and physical examination) and determine
eligibility according to the inclusion and exclusion
criteria (Table 1). All mini-facelift procedures will be
performed by the same surgeon. Prior to enrollment,
a screening photosensitivity test will be conducted,
wherein the potential subject will be exposed to LED-
RL for 20 min on the non-dominant upper forearm,
and then evaluated in clinic 24 h later for evidence of
photosensitivity [32–34]. Criteria for photosensitivity
include, but are not limited to, warmth, erythema,
edema, rash, pain, or discomfort lasting more than
24 h. If no photosensitive reactions are noted, the
subject will be eligible to enroll in the study.
Study design
This is a dose-ranging, randomized, parallel group,
split-face, single-blind, mock-controlled, phase II
study to evaluate the efficacy of LED-RL in reducing
skin fibrosis in subjects who will undergo elective
mini-facelift surgery. Refer to Fig. 1 for a schematic
of the study design. Starting one week after surgery
(defined as postoperative days 4 to 8), subjects will
receive LED-RL phototherapy to the periauricular
skin incision sites. Beginning scar reduction therapy
one week after surgery is a validated intervention
time point for limiting surgical scars [35]. The max-
imum recommended starting dose of 160 J/cm2 is
based on previously published maximum doses of
LED-RL that demonstrated safety with no AEs in
clinical studies [36, 37]. The highest dose to be
tested is 480 J/cm2, which was found to be the max-
imum tolerated dose (MTD) in our phase I studies
(unpublished data). The MTD is defined as the dose
level below the dose producing unacceptable but
Table 1 Eligibility criteria for the CURES trial
Inclusion criteria Exclusion criteria
• Provision of written informed
consent for all study procedures
• Stated willingness to comply
with all study procedures and
availability for the duration of the
study
• Suitable candidate for elective
mini-facelift surgery
• Pass a screening photosensitivity
test
• Current use of any
photosensitizing medications
• Light-sensitive conditions
• Diabetes mellitus
• Systemic lupus erythematosus
• Current tobacco use
• History of bleeding or coagulation
disorder
• Lax skin associated with genetic
disorders
• Open wounds on the face or
neck
• Fibrotic skin disease, pre-existing
scar(s), or other skin conditions af-
fecting the periauricular skin
• History of surgery or procedure
involving or affecting the
periauricular skin within the past
6 months (e.g., prior facelift, fillers,
laser therapy)
• Tattoos that cover the proposed
treatment sites on the
periauricular skin
• Any other medical condition(s)
that could be compromised by
exposure to the proposed
treatment
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reversible toxicity and is considered to be the upper
limit of subject tolerance.
A total of 30 subjects will be randomly allocated to three
treatment groups of ten subjects each to receive LED-RL
phototherapy at the following fluences (doses): 160 J/cm2,
320 J/cm2, or 480 J/cm2. The treatment side (right face
versus left face) will also be randomized to control for
possible effects of uneven sun exposure. The untreated
side will receive temperature-matched mock irradiation
via a mock device that looks, sounds, and feels similar to
the treatment device, but does not produce light. Subjects
will receive their treatment sessions in-office three times
weekly, a standard phototherapy regimen, for three con-
secutive weeks (i.e., a total of nine treatment sessions)
[38–40]. This treatment schedule reflects the regimen im-
plemented in our phase I studies [32]. Following the study
intervention period, subjects will have follow-up assess-
ments for outcome measures on approximately postoper-
ative days (POD) 30, 90, and 180.
Study devices
The LED-RL source is the Omnilux handheld LED system
(GlobalMed Technologies, Glen Ellen, CA, USA). This
LED-RL array device is commercially available as the
Omnilux clear-U and Omnilux new-U, which are FDA-
cleared for the treatment of facial acne and periorbital
rhytides, respectively [33, 34, 41, 42]. The treatment de-
vice has a 4.7 cm × 6.1 cm rectangular array of LEDs and
emits visible red light (633 ± 6 nm) at a power density of
360.2W/m2 at room temperature and a distance of 10
mm from the target surface [30, 33, 34]. The mock ther-
apy device is designed to sound, look, and feel identical to
the LED-RL treatment device (i.e., has the same physical
components and thermal output), except it does not emit
visible red light [32]. The use of mock irradiation as a con-
trol ensures that any measured clinical effect is a result of
LED-RL treatment and not due to ambient light, environ-
ment, or temperature [31]. The LED-RL treatment and
mock therapy devices will be tracked using the manufac-
turer’s serial numbers.
Study treatment
At the start of every treatment session, the subject’s peri-
auricular skin on both sides of the face will be cleaned
with alcohol pads and the treatment area will be out-
lined with a surgical marking pen, then photographed
Fig. 1 Study design for the CURES trial. LED-RL light emitting diode-red light, POD postoperative day
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prior to device placement. The LED-RL treatment device
and mock therapy device will be positioned in close con-
tact with the periauricular skin (maximum distance of
10 mm from the skin surface), securely held in place for
the duration of the treatment. LED-RL phototherapy
and mock therapy will be administered simultaneously.
Subjects will wear safety goggles during the treatment
sessions, as recommended by Omnilux for comfort;
there are no known ocular sequelae to LED-RL irradi-
ation and the Omnilux devices have been tested to inter-
national standards to ensure that the outputs are safe for
the eyes [33, 34]. The research coordinator will observe
the treatment and monitor for any AEs or safety issues
that may arise. Since the power density of LED-RL will
remain constant across all treatment groups, the total
fluence of LED-RL delivered depends on the exposure
time to phototherapy [43]. The duration of the treat-
ment administration for each treatment group is as
follows:
 Group 1: LED-RL 160 J/cm2 and mock therapy (30
min)
 Group 2: LED-RL 320 J/cm2 and mock therapy (60
min)
 Group 3: LED-RL 480 J/cm2 and mock therapy (90
min)
Concomitant therapy
A review of concomitant medications will be performed at
each study visit. The concurrent use of photosensitizing
medications is a contraindication to LED phototherapy
[18, 44]. Therefore, during the three-week intervention
period, the following medications that are known to have
photosensitizing properties will be prohibited: amioda-
rone, azathioprine, chlorpromazine, gold, griseofulvin,
isotretinoin, lithium, melatonin, methotrexate, phenothia-
zine antipsychotics, tetracycline antibiotics, and quinolone
derivative antibiotics. For the entire duration of the study,
subjects will be asked to avoid scar treatments to both
periauricular incision sites (with the exception of topical
agents recommended for routine postoperative wound
care), as to not confound the results of the study. Scar
treatments include, but are not limited to, silicone gels/
sheets, intralesional corticosteroids, 5-fluorouracil, laser
therapy, radiotherapy, cryotherapy, bleomycin, mitomycin
C, imiquimod, pressure therapy, adhesive microporous
hypoallergenic paper tape, onion extract, massage therapy,
over-the-counter topical emollients for scars, laser ther-
apy, and surgical revision [13].
Efficacy assessments
Efficacy assessments for outcome measures will be con-
ducted at baseline (i.e., at the first treatment session,
prior to initiation of LED-RL phototherapy) and at
follow-up visits on approximately POD 30 (1 month),
POD 90 (3 months), and POD 180 (6 months). The eval-
uations at multiple time points will allow comparison of
the difference between treated and control sites over
time as the post-surgical scars heal and mature.
Primary outcome measures
The primary endpoint is the difference in quantitative
scar pliability between the treated and control incision
sites at 1 month, 3 months, and 6 months after surgery.
The time point of primary interest is the final assessment at
6months. Skin elasticity and skin induration are two separ-
ate indices for scar pliability and will be objectively mea-
sured using the ElastiMeter and the SkinFibroMeter (Delfin
Technologies, Kuopio, Finland), respectively, which have
been shown to be accurate and reliable to assess skin fibro-
sis [45–47]. These non-invasive instruments have an in-
denter and force sensors to measure the force resisting
vertical deformation of the skin surface [48]. Scar tissue is
thicker than normal skin and therefore is expected to be
firmer and less compliant (i.e., more stiff) [49, 50]. The
measurements will be taken at the midpoint of width and
length of each scar to ensure that recurrent measurements
will be in the same anatomic location.
Secondary outcome measures
Standardized scar evaluations using the POSAS will be
performed by the same investigator (who is blinded to
the treatment or control site) in conjunction with the
subject at baseline and each follow-up visit. The POSAS
is a validated tool to evaluate post-surgical linear scars
and is commonly used in clinical trials to assess scar
quality in response to treatment [51–54]. The two sub-
scales of the POSAS each consist of six items rated from
1 to 10, where 1 is “normal skin” and 10 is the “worst
imaginable scar”. The observer (i.e., investigator) evalu-
ates scar vascularity, pigmentation, thickness, relief, pli-
ability, and surface area while the patient assesses pain,
itching, color, stiffness, thickness, and irregularity. The
scores of each of the six items are summed for a total
score (range 6 to 60). Importantly, the POSAS incorpo-
rates the patient’s judgment of scar appearance and
includes subjective symptoms of pain and pruritus,
allowing for a more comprehensive evaluation of treat-
ment response and patient-reported outcomes [50, 55].
Standardized digital photographs of the incision sites
will be taken at baseline and each follow-up visit. The scar
images will be rated by two independent, blinded derma-
tologists using a visual analogue scale (VAS). The VAS is
presented as a 10-cm horizontal line, where the extreme
ends of 0 indicates “normal skin” and 10 corresponds to
the “worst possible scar”, for each of the following scar
attributes: pigmentation, vascularity, observer comfort,
contour, and overall severity [49, 56]. The evaluators will
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also be presented with paired scar images (i.e., LED-RL-
treated scar paired with its matched control site) and
asked to rank which scar appears better. The
photographic-based VAS scoring and ranking system has
been shown to be consistent, reliable, and valid for linear
scar assessment [57].
Secondary outcome measures will also include object-
ive measurements of important scar characteristics such
as physiological properties, dimensions, and color. A
non-invasive, handheld diffuse reflectance probe will be
used to measure collagen and water concentration in
the dermis at the midpoint of the scars [58]. A 3D
digital imaging system will be used to construct 3D im-
ages of the scars for skin profilometry and colorimetric
analyses, including quantitative measurements of tex-
ture, pigmentation, vascularity, surface area, and tissue
volume [59–61].
Histological and molecular studies
The histological and molecular changes that occur in vivo
in response to LED-RL phototherapy will be evaluated by
examination of pre- and post-treated skin tissue. Skin
specimens will be obtained via optional 2mm punch bi-
opsy on POD 0 (from excised periauricular skin on the
day of surgery) and POD 30 (post-treatment incision sites
at the first follow-up visit). Subjects will have the option
to decline biopsies and remain in the study. Histological
examination of skin specimens will be conducted to quan-
tify the number of Ki-67 positive fibroblasts and to assess
collagen content [62]. High-throughput assays will be per-
formed, including RNA sequencing, microRNA arrays, and
quantitative real-time PCR, to screen for molecular effects
(e.g., changes in gene expression) associated with LED-RL
exposure.
Safety assessment
Subjects will be provided with a daily diary to record
any AEs experienced during the 3-week intervention
period, and will also be called weekly to monitor for
AEs. Treatment sessions will be monitored closely for
the occurrence of any safety issues or AEs, as reported
by the subject or observed by the clinical research team.
The incision sites will also be photographed before and
after each treatment administration for visual documen-
tation of the subject’s initial presentation and any subse-
quent changes. All AEs will be documented in the
appropriate case report form (CRF) with details includ-
ing the event description, time of onset, severity, rela-
tionship to the study intervention, and outcome. An AE
is defined as any untoward medical occurrence associ-
ated with the use of the study intervention, whether or
not considered to be causally related [63]. All AEs will
be followed for outcome information until adequate
resolution or stabilization. Common expected post-
treatment side effects, including warmth, redness, and
swelling, are expected to be transient (i.e., last less than
24 h) and will be recorded, but will not be considered
AEs in safety data reports [32]. The study may be halted
or a subject may be withdrawn from the study if neces-
sary for safety reasons, such as the occurrence of serious
AEs (e.g., second-degree or higher skin burning, severe
blistering, persistent swelling or pain, ulceration, change
in sensation, muscle weakness, worsening of scar).
Randomization
All subjects will be assigned to the treatment group and
LED-RL treatment side simultaneously as they are en-
rolled by the research coordinator. A block randomization
scheme will be used to ensure balanced allocation of sub-
jects to the study arms, such that ten subjects are assigned
to each treatment group (i.e., allocation ratio 1:1:1) and
such that equal numbers receive LED-RL to the right face
and left face (Fig. 1). The block sizes will not be disclosed
to ensure concealment. The allocation sequence will be
generated by a research assistant not involved in enrolling
participants or assigning interventions, using a computer-
based random number generator [64]. Individual assign-
ments to Group 1 (LED-RL 160 J/cm2), Group 2 (LED-RL
320 J/cm2), or Group 3 (LED-RL 480 J/cm2) as well as the
LED-RL treatment side (right versus left) will be concealed
together in sequentially numbered, opaque, sealed enve-
lopes until the time of enrollment.
Blinding
Subjects will be blinded to the study intervention (LED-
RL phototherapy versus mock therapy) as the treatment
area is outside of the range of view and the study devices
are indistinguishable. Clinicians involved in subjective effi-
cacy assessments will be also be blinded. This includes the
investigator performing the POSAS, the two independent
dermatologists evaluating the scar photographs, and the
dermatopathologist examining the skin specimens. The
principal investigator (PI), along with the research coord-
inator who administers the LED-RL phototherapy, will be
aware of each subject’s treatment assignment. Unblinding
may occur at the discretion of the PI in exceptional cir-
cumstances, such as when knowledge of the study inter-
vention is needed to treat a serious AE.
Time frame
This study is designed to conclude in 12months, which
includes subject screening and enrollment, study interven-
tion, follow-up for efficacy assessments, and data analysis.
The full schedule of clinical trial activities is available in
accordance with SPIRIT guidelines (Additional file 1).
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Sample size justification
This clinical trial is intended to be a pilot study to obtain
estimates of feasibility and outcome variability, as there is
a paucity of background data in the literature. These pre-
cise estimates will aid in the planning of a larger, suffi-
ciently powered efficacy trial. We estimate that a
difference of 15% in scar pliability will be clinically mean-
ingful, based on the minimum decrease in fibroblast num-
ber in response to LED-RL irradiation from our in vitro
data [29]. A sample size of 30 subjects (with the split-face,
intra-individual comparison design) will allow for a precise
estimate of the variance in scar pliability change in this
population.
Statistical analysis
SAS version 9.4 statistical package (SAS Institute, Cary,
NC, USA) will be used for intention-to-treat analysis (for
all available data) and per-protocol analysis (for subjects
with complete data). The primary outcome measures will
be used separately as dependent variables (DVs) in mixed
linear models. Fixed factors in each model will be treat-
ment group, whether treated, side of face (left versus
right), and time (three follow-up assessments post-
baseline). Baseline DV measure will be introduced as a
scored covariate, with subject identification as a random
factor. The Akaike information criterion will be used to
assess what intra-subject covariance structure might be
optimal. Tests of interaction among fixed factors will be
conducted and the utility of polynomial terms in the base-
line DV investigated. Model residuals will be examined for
skew and for outliers; the DV will be power-transformed if
necessary to maximize normality of residuals. Secondary
outcomes will be presented as descriptive statistics tabu-
lated by whether treated, treatment group, and time. No
inferential analyses will be conducted in order to minimize
the multiple testing problem.
Summary statistics of safety data will be presented as
number of subjects who experienced AEs in each treat-
ment group and a breakdown of the event types. Descrip-
tive statistics of relevant subject characteristics (age,
gender, race, and ethnicity) of the study population will be
tabulated by treatment group. Continuous variables will
be presented as median and range. Categorical variables
will be presented as proportions. Significance tests will
not be applied. To determine if any differential effects of
LED-RL are associated with demographics, a linear regres-
sion or robust linear regression with adjustment for treat-
ment group effect on scar pliability will be performed.
Data management and monitoring
All individual subject data required by the study
protocol will be recorded in the appropriate CRFs as
well as in a 21 CFR Part 11-compliant data capture
system, in accordance with the International
Conference on Harmonisation (ICH) Good Clinical
Practice (GCP) guidelines. All source documents will
be de-identified, securely maintained, and protected
for confidentiality in accordance with the SUNY
Downstate Institutional Review Board (IRB) policies.
Research records will be accessible to the research co-
ordinator, investigators, and data/safety monitoring
personnel as required.
A data monitoring committee (DMC) composed of
three board-certified dermatologists, independent
from the study conduct and free of conflict of inter-
est, will be responsible for safety oversight and clin-
ical monitoring. The DMC will convene on a
quarterly basis to review any AEs and safety issues.
All AEs and serious AEs will be reported to the IRB
and DMC within the timelines specified in the SUNY
Downstate IRB policy for human research protections.
The PI will have access to interim results and be able
to make the final decision to terminate the study.
Discussion
To our knowledge, no prior clinical trials have been
performed to determine the safety and efficacy of
LED-RL phototherapy for the treatment or preven-
tion of skin fibrosis. This study may provide import-
ant data on LED-RL phototherapy as a therapeutic
modality for post-surgical skin scarring, and help to
facilitate future clinical trials to further evaluate the
efficacy of LED-RL in comparison to existing anti-
fibrotic therapeutics for various types of tissue
fibrosis.
While scar formation is an expected outcome of
wound healing after cutaneous injury, it can range from
faint scarring to severe thickening and tightening of the
skin [65]. Scar prevention is a key consideration in
postoperative wound management, as scarring has
significant aesthetic and functional consequences for
patients [66, 67]. While scar revision (i.e., treatment of
existing scars) has been the mainstay of therapy, recent
advances in the understanding of wound healing mech-
anisms have inspired innovative strategies to prevent
scar formation [68–70]. As in vitro data show that
LED-RL can attenuate profibrotic cellular processes
that contribute to skin fibrosis, LED-RL is a promising
strategy to minimize scar formation after surgery [29,
31]. In this study, LED-RL phototherapy will be initi-
ated within one week post-surgery (defined as POD 4–
8), coinciding with the early proliferation phase of
wound healing, which will help to answer important
questions about the impact of intervention time on final
scar outcomes [71–73].
The methodology described in this protocol offers sev-
eral advantages compared to other clinical trials that
evaluate scar management strategies. The split-face
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study design allows each subject to serve as his or her
own control, such that comparisons of clinical efficacy
between treated and control scars are within-subject
(i.e., intra-individual). Therefore, any measured changes
in scar characteristics can be attributed to the treatment,
eliminating the confounding factor of inter-individual
differences in wound healing. It is important to note that
in the prospective evaluation of scar reduction therapy,
it is assumed that, if left untreated, the bilateral facelift
incisions would heal with identical scars. Since wound
healing and scar formation are influenced by many vari-
ables, a self-controlled study design is favorable to allow
detection of true treatment effects. Furthermore, the
treated side of the face will be randomized to account
for possible differences in the laterality of photodamaged
skin (e.g., asymmetry of sun exposure in automobile
drivers) [74].
A dose-ranging study design is implemented as the
safety of LED-RL phototherapy in a facelift scar
model may differ from the safety in normal skin. For
example, LED-RL fluences determined to be safe in
normal forearm skin (the treatment site in STARS 1
and STARS 2) may have different effects on the face,
as physiological properties of skin vary depending on
anatomic location [75, 76]. Thus, the MTD estab-
lished in our phase I studies serves as the upper limit
of treatment dose in this study.
This study may have several potential limitations.
There may be a bias in age toward middle-aged and
elderly individuals, as the majority of facelift patients
are over the age of 50 years (mean 59 years) [77, 78].
Increased age is associated with reduced collagen
turnover due to a decrease in fibroblast collagen syn-
thesis; therefore, the penetration of LED-RL may be
affected and certain fluences that result in AEs may
vary among different age groups [79, 80]. Further-
more, since cell turnover is a major contributor to
the development of scar tissue in a healing wound,
elderly individuals tend to have better outcomes for
scar cosmesis and are less susceptible to exuberant,
pathologic scarring [81–84].
Limited data exist regarding the cutaneous effects of
LED-RL on different skin types and ethnicities. Based on
the safety data generated in our phase I studies, we hy-
pothesized that LED-RL may exhibit differential biologic
effects depending on ethnicity, with skin of color indi-
viduals being more photosensitive to LED-RL compared
to Caucasian non-Hispanic individuals. To further ex-
plore this observation, this study will test the MTD of
480 J/cm2 in all subjects regardless of skin type, and sub-
group analyses will be performed to assess any differ-
ences in AEs based on demographics.
There is a large unmet need for innovative therapeutic
strategies to manage skin fibrosis, such as excessive scar
formation after surgery [85]. Despite the substantial
healthcare burden of skin fibrosis, there is no “gold
standard” or universally effective scar therapy, and
current treatment options have limited clinical efficacy
[12, 67, 86]. Therefore, successful demonstration of the
efficacy of LED-RL phototherapy in limiting skin fibrosis
may revolutionize the current treatment paradigm for fi-
brotic skin diseases. Future studies may extend beyond
scar prevention and investigate the use of LED-RL to
treat existing scars.
Trial status
The final protocol version is 4.1 and dated 4 April 2019.
This study began recruiting subjects on 18 March 2019
at SUNY Downstate Medical Center, Brooklyn, NY,
USA. We expect all participants to be enrolled by 1 July
2019.
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Additional file 2: SPIRIT Checklist. (PDF 1055 kb)
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